• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧盟/欧洲经济区具有多重风险因素的重点人群中乙型和丙型肝炎的流行率和发病率:系统评价。

Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review.

机构信息

Pallas Health Research and Consultancy B.V., Rotterdam, Netherlands.

European Centre for Disease Prevention and Control, Stockholm, Sweden.

出版信息

Euro Surveill. 2019 Jul;24(30). doi: 10.2807/1560-7917.ES.2019.24.30.1800614.

DOI:10.2807/1560-7917.ES.2019.24.30.1800614
PMID:31362808
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6668290/
Abstract

BackgroundPeople living with HIV (PLHIV) and people in prison are population groups with a potentially high risk and/or prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.AimWe conducted a systematic review in order to find prevalence and incidence estimates in these populations in the European Union/European Economic Area (EU/EEA).MethodsOriginal research articles published between January 2005 and February 2017 were retrieved from PubMed and Embase in February 2017.ResultsFifty-two articles were included, providing 97 estimates of HBV/HCV infection prevalence or incidence. Estimates of HBV infection prevalence ranged between 2.9% and43.4% in PLHIV and 0.0% and 25.2% in people in prison. Estimates of HCV infection prevalence ranged from 2.9% to 43.4% in PLHIV and 0.0% to 25.2% in people in prison. Incidence estimates ranged between 0.0 and 2.5 cases per 100 person-years for HBV infection in PLHIV. No such data was available for people in prison. HCV infection incidence ranged between 0.3 and 0.9 cases per 100 person-years in PLHIV and between 1 and 1.2 cases per 100 person-years in people in prison. Prevalence estimates were generally higher than in the general population, especially for HCV infection and among groups with multiple risk factors.ConclusionsPLHIV, people in prison and groups with multiple risk factors, have a high prevalence of HBV and HCV and may be at ongoing risk of infection. These groups should be among the populations prioritised and targeted for active case finding and prevention programmes in the EU/EEA.

摘要

背景

艾滋病毒感染者(PLHIV)和囚犯是具有较高乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染风险和/或流行率的人群。

目的

我们进行了系统评价,以确定欧盟/欧洲经济区(EU/EEA)中这些人群的流行率和发病率估计值。

方法

于 2017 年 2 月从 PubMed 和 Embase 检索了 2005 年 1 月至 2017 年 2 月期间发表的原始研究文章。

结果

共纳入 52 篇文章,提供了 97 项 HBV/HCV 感染流行率或发病率的估计值。PLHIV 中 HBV 感染流行率的估计值范围为 2.9%至 43.4%,囚犯中为 0.0%至 25.2%。PLHIV 中 HCV 感染流行率的估计值范围为 2.9%至 43.4%,囚犯中为 0.0%至 25.2%。PLHIV 中 HBV 感染的发病率估计值在每 100 人年 0.0 至 2.5 例之间。关于囚犯,没有此类数据。PLHIV 中 HCV 感染的发病率估计值在每 100 人年 0.3 至 0.9 例之间,囚犯中为每 100 人年 1 至 1.2 例。流行率估计值通常高于一般人群,尤其是 HCV 感染和具有多种危险因素的人群。

结论

PLHIV、囚犯和具有多种危险因素的人群 HBV 和 HCV 的流行率较高,并且可能持续存在感染风险。这些人群应是欧盟/欧洲经济区优先和有针对性地开展主动病例发现和预防规划的人群。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a2e/6668290/8a46e1cf6223/1800614-fa.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a2e/6668290/8a46e1cf6223/1800614-fa.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a2e/6668290/8a46e1cf6223/1800614-fa.jpg

相似文献

1
Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review.欧盟/欧洲经济区具有多重风险因素的重点人群中乙型和丙型肝炎的流行率和发病率:系统评价。
Euro Surveill. 2019 Jul;24(30). doi: 10.2807/1560-7917.ES.2019.24.30.1800614.
2
Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.欧盟/欧洲经济区国家的乙型/丙型肝炎:对高危人群患病率的系统评价。
BMC Infect Dis. 2018 Feb 12;18(1):79. doi: 10.1186/s12879-018-2988-x.
3
Seroprevalence of hepatitis B virus and hepatitis C virus co-infection among people living with HIV/AIDS visiting antiretroviral therapy centres in Nepal: a first nationally representative study.尼泊尔接受抗逆转录病毒治疗的艾滋病毒/艾滋病患者中乙型肝炎病毒和丙型肝炎病毒合并感染的血清流行率:一项全国性的首次代表性研究。
Int J Infect Dis. 2017 Jul;60:64-69. doi: 10.1016/j.ijid.2017.04.011. Epub 2017 May 5.
4
Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States.三座监狱中乙型和丙型肝炎病毒感染率及与艾滋病毒的合并感染情况:美国监狱中病毒性肝炎预防的一个实例
J Urban Health. 2009 Jan;86(1):93-105. doi: 10.1007/s11524-008-9305-8. Epub 2008 Jul 12.
5
Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria.人类免疫缺陷病毒、乙型肝炎病毒和丙型肝炎病毒:尼日利亚纳萨拉瓦州监狱囚犯中的血清流行率、合并感染及危险因素
J Infect Dev Ctries. 2009 Aug 30;3(7):539-47. doi: 10.3855/jidc.472.
6
Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis.非洲人类免疫缺陷病毒感染者中乙型肝炎病毒和/或丙型肝炎病毒感染的流行病学:系统评价和荟萃分析。
PLoS One. 2022 May 31;17(5):e0269250. doi: 10.1371/journal.pone.0269250. eCollection 2022.
7
Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa.在南非农村地区感染 HIV 的人群中,虽然存在隐匿性乙型肝炎病毒,但乙型肝炎病毒和丙型肝炎病毒的活动性感染近乎不存在。
J Med Virol. 2011 Jun;83(6):929-34. doi: 10.1002/jmv.22026.
8
Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update.欧盟/欧洲经济区一般人群和高危人群丙型肝炎感染率:系统评价更新。
BMC Infect Dis. 2019 Jul 23;19(1):655. doi: 10.1186/s12879-019-4284-9.
9
Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy.意大利监狱服刑人员中HIV、HBV和HCV感染的相关因素:一项多中心研究的结果
J Med Virol. 2005 Jul;76(3):311-7. doi: 10.1002/jmv.20375.
10
The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: a systematic review and meta-analysis.全球和区域范围内,合并感染 HIV 的囚犯中丙型肝炎和乙型肝炎的流行情况:系统评价和荟萃分析。
Infect Dis Poverty. 2021 Jul 1;10(1):93. doi: 10.1186/s40249-021-00876-7.

引用本文的文献

1
The burden of viral hepatitis infection and mortality: Findings from a population-based study in Poland over 2009-2023.病毒性肝炎感染和死亡率负担:2009年至2023年波兰一项基于人群研究的结果
Clin Exp Hepatol. 2025 Jun;11(2):137-146. doi: 10.5114/ceh.2025.151703. Epub 2025 Jun 26.
2
Evaluating the effectiveness of a population-level health intervention to increment HCV treatment coverage in tuscany region, Italy: An interrupted time series analysis.评估一项旨在提高意大利托斯卡纳地区丙型肝炎病毒(HCV)治疗覆盖率的人群层面健康干预措施的有效性:一项中断时间序列分析。
PLoS One. 2025 May 16;20(5):e0306733. doi: 10.1371/journal.pone.0306733. eCollection 2025.
3

本文引用的文献

1
Prevalence of Drug Injection, Sexual Activity, Tattooing, and Piercing Among Prison Inmates.囚犯中药物注射、性行为、纹身和穿孔的流行情况。
Epidemiol Rev. 2018 Jun 1;40(1):58-69. doi: 10.1093/epirev/mxy002.
2
HIV and Viral Hepatitis Among Imprisoned Key Populations.羁押人群中的艾滋病毒和病毒性肝炎
Epidemiol Rev. 2018 Jun 1;40(1):12-26. doi: 10.1093/epirev/mxy003.
3
Active Case Finding for Communicable Diseases in Prison Settings: Increasing Testing Coverage and Uptake Among the Prison Population in the European Union/European Economic Area.
Diagnostic performance of hepatitis C virus core antigen testing for detecting hepatitis C in people living with hepatitis B: a systematic review and meta-analysis.
丙型肝炎病毒核心抗原检测在乙型肝炎患者中检测丙型肝炎的诊断性能:一项系统评价和荟萃分析
Infect Dis Poverty. 2024 Dec 2;13(1):89. doi: 10.1186/s40249-024-01264-7.
4
HBV in Italian Women's Jail: An Underestimated Problem?意大利女子监狱中的乙肝病毒:一个被低估的问题?
J Clin Med. 2024 Feb 28;13(5):1398. doi: 10.3390/jcm13051398.
5
Evaluating hepatitis C cascade of care surveillance system in Tuscany, Italy, through a population retrospective data-linkage study, 2015-2021.评估意大利托斯卡纳地区丙型肝炎关怀监测系统:一项基于人群的回顾性数据链接研究,2015-2021 年。
BMC Infect Dis. 2024 Mar 29;24(1):362. doi: 10.1186/s12879-024-09241-z.
6
What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?长效型 HIV 暴露前预防性投药的推广对全球乙型肝炎疫情意味着什么?
J Int AIDS Soc. 2024 Mar;27(3):e26218. doi: 10.1002/jia2.26218.
7
Procedural fairness in benefit package design: inclusion of pre-exposure prophylaxis of HIV in Universal Coverage Scheme in Thailand.程序公平性在福利套餐设计中的应用:泰国全民医疗保险计划纳入艾滋病毒暴露前预防。
Health Policy Plan. 2023 Nov 14;38(Supplement_1):i36-i48. doi: 10.1093/heapol/czad061.
8
Implementation of the HepC test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysis.针对居住在西班牙加泰罗尼亚的丙型肝炎巴基斯坦移民实施 HepC 检测和治疗社区策略与加泰罗尼亚卫生系统现行做法的比较:预算影响分析。
BMJ Open. 2023 Aug 21;13(8):e068460. doi: 10.1136/bmjopen-2022-068460.
9
Estimates of hepatitis B virus prevalence among general population and key risk groups in EU/EEA/UK countries: a systematic review.欧盟/欧洲经济区/英国国家普通人群和重点风险人群乙型肝炎病毒流行率估计:系统评价。
Euro Surveill. 2023 Jul;28(30). doi: 10.2807/1560-7917.ES.2023.28.30.2200738.
10
Estimating hepatitis B virus prevalence among key population groups for European Union and European Economic Area countries and the United Kingdom: a modelling study.估算欧盟及欧洲经济区国家和英国重点人群乙型肝炎病毒流行率:建模研究。
BMC Infect Dis. 2023 Jul 10;23(1):457. doi: 10.1186/s12879-023-08433-3.
监狱环境中的传染病主动病例发现:提高欧盟/欧洲经济区监狱人口的检测覆盖率和参与度。
Epidemiol Rev. 2018 Jun 1;40(1):105-120. doi: 10.1093/epirev/mxy001.
4
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.2016 年全球乙型肝炎病毒感染的流行率、治疗和预防:一项建模研究。
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6. Epub 2018 Mar 27.
5
Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014.2006 至 2014 年欧盟/欧洲经济区国家乙型肝炎疫苗接种对急性乙型肝炎流行病学的影响。
Euro Surveill. 2018 Feb;23(6). doi: 10.2807/1560-7917.ES.2018.23.6.17-00278.
6
Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy.荷兰男男性行为人群中丙型肝炎病毒(HCV)发病率下降,与 HCV 治疗不受限制后获得性免疫缺陷病毒(HIV)阳性相关。
Clin Infect Dis. 2018 Apr 17;66(9):1360-1365. doi: 10.1093/cid/cix1007.
7
Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.分散式与集中式药物替代方案中丙型肝炎的管理以及用于弥合丙型肝炎病毒治疗流程差距的微创即时检测
Swiss Med Wkly. 2017 Nov 20;147:w14544. doi: 10.4414/smw.2017.14544. eCollection 2017.
8
A large proportion of people who inject drugs are susceptible to hepatitis B: Results from a bio-behavioural study in eight German cities.相当大比例的吸毒者易感染乙型肝炎:来自德国八个城市的生物行为研究结果。
Int J Infect Dis. 2018 Jan;66:5-13. doi: 10.1016/j.ijid.2017.10.008. Epub 2017 Oct 31.
9
Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review.欧盟/欧洲经济区普通人群、献血者及孕妇中慢性乙型和丙型肝炎病毒感染的当前流行情况:一项系统综述
Epidemiol Infect. 2017 Oct;145(14):2873-2885. doi: 10.1017/S0950268817001947. Epub 2017 Sep 11.
10
Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.通过任务转移至社区非专科医疗人员扩大丙型肝炎病毒感染治疗:一项非随机临床试验
Ann Intern Med. 2017 Sep 5;167(5):311-318. doi: 10.7326/M17-0118. Epub 2017 Aug 8.